eicosapentaenoic acid ethyl ester has been researched along with Depressive Disorder in 7 studies
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare the efficacy of ethyl-eicosapentaenoic acid (E-EPA) and placebo in the treatment of female subjects with borderline personality disorder." | 5.10 | omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. ( Frankenburg, FR; Zanarini, MC, 2003) |
| " All of the individual items on all 3 rating scales improved with the 1-g/d dosage of ethyl-eicosapentaenoate vs placebo, with strong beneficial effects on items rating depression, anxiety, sleep, lassitude, libido, and suicidality." | 2.70 | A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. ( Horrobin, DF; Peet, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, Z | 1 |
| Zhang, C | 1 |
| Yan, L | 1 |
| Zhang, Y | 1 |
| Yang, Z | 1 |
| Wang, J | 1 |
| Song, C | 2 |
| Tayama, J | 1 |
| Ogawa, S | 1 |
| Nakaya, N | 1 |
| Sone, T | 1 |
| Hamaguchi, T | 1 |
| Takeoka, A | 1 |
| Hamazaki, K | 1 |
| Okamura, H | 1 |
| Yajima, J | 1 |
| Kobayashi, M | 1 |
| Hayashida, M | 1 |
| Shirabe, S | 1 |
| Zhang, XY | 1 |
| Manku, M | 1 |
| Peet, M | 1 |
| Horrobin, DF | 1 |
| Zanarini, MC | 1 |
| Frankenburg, FR | 1 |
| Chiu, CC | 1 |
| Huang, SY | 1 |
| Shen, WW | 1 |
| Su, KP | 1 |
| Nemets, B | 1 |
| Stahl, Z | 1 |
| Belmaker, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis[NCT00122954] | Phase 1/Phase 2 | 39 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder[NCT04210804] | Phase 2 | 80 participants (Actual) | Interventional | 2014-04-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Higher MADRS scores indicate more severe depression, and the overall score ranges from 0-60. A score of 0-6 indicates symptoms absent, 7-19 indicates mild depression, 20-34 moderate, and > 34 severe. Our primary outcome was 50% or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS). (NCT00122954)
Timeframe: baseline to 3 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Placebo | 45.5 |
| Omega-3 Fatty Acids | 47.4 |
SF-36 is a commonly used measure of health-related quality of life and is well validated in many disease conditions. Responses are self-administered and responses are summed into two subscores, the mental component summary (MCS) and physical component summary (PCS). The SF-36 has eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed on a 0-100 scale. Higher scores represent higher function. (NCT00122954)
Timeframe: baseline to 3 months
| Intervention | mean change of units on a scale (Mean) | |
|---|---|---|
| Physical (PCS) | Mental (MCS) | |
| Omega-3 Fatty Acids | 1.6 | 1.5 |
| Placebo | -0.8 | 4.2 |
4 trials available for eicosapentaenoic acid ethyl ester and Depressive Disorder
| Article | Year |
|---|---|
Omega-3 polyunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: A double-blind randomized controlled trial.
Topics: Adult; Combined Modality Therapy; Depression; Depressive Disorder; Dietary Supplements; Docosahexaen | 2019 |
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response R | 2002 |
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response R | 2002 |
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response R | 2002 |
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response R | 2002 |
omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.
Topics: Adult; Aggression; Borderline Personality Disorder; Depressive Disorder; Double-Blind Method; Drug T | 2003 |
Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Therapy, Combinat | 2002 |
Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Therapy, Combinat | 2002 |
Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Therapy, Combinat | 2002 |
Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Therapy, Combinat | 2002 |
3 other studies available for eicosapentaenoic acid ethyl ester and Depressive Disorder
| Article | Year |
|---|---|
EPA is More Effective than DHA to Improve Depression-Like Behavior, Glia Cell Dysfunction and Hippcampal Apoptosis Signaling in a Chronic Stress-Induced Rat Model of Depression.
Topics: Animals; Apoptosis; Behavior, Animal; Depressive Disorder; Docosahexaenoic Acids; Eicosapentaenoic A | 2020 |
Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment.
Topics: Analysis of Variance; Animals; Celecoxib; Corticosterone; Corticotropin-Releasing Hormone; Cyclooxyg | 2009 |
Omega-3 fatty acids for depression in pregnancy.
Topics: Adult; Depressive Disorder; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fema | 2003 |